The changing face of mantle cell lymphoma.

被引：0
|
作者：
Goepel, JR
Lorigan, PC
Vandenberghe, EA
Allen, JE
Hammond, DW
Hancock, BW
机构：
[1] Royal Hallamshire Hosp, Dept Haematol, Sheffield S10 2JF, S Yorkshire, England
[2] Royal Hallamshire Hosp, Inst Canc Studies, Sheffield S10 2JF, S Yorkshire, England
[3] Royal Hallamshire Hosp, Dept Pathol, Sheffield S10 2JF, S Yorkshire, England
[4] Weston Pk Hosp, Yorkshire Canc Res Dept Clin Oncol, Sheffield, S Yorkshire, England
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
006
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [21] CD5 negative mantle cell lymphoma.
    Liu, Z
    Dong, H
    Gorczyca, W
    Tsang, P
    Cohen, P
    Stephenson, C
    Berger, C
    Wu, CD
    Weisberger, J
    BLOOD, 2001, 98 (11) : 126A - 126A
  • [22] Outcomes of autologous and allogeneic BMT for mantle cell lymphoma.
    Kasamon, YL
    Jones, RJ
    Diehl, LF
    Nayer, H
    Borowitz, MJ
    Garrett-Mayer, E
    Ambinder, RF
    Abrams, RA
    Zhang, Z
    Flinn, IW
    BLOOD, 2004, 104 (11) : 257A - 257A
  • [23] Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): A Valuable Tool for Risk Stratification in Mantle Cell Lymphoma.
    Smith, Stephen Douglas
    Hsi, Eric D.
    Bolwell, Brian J.
    Maggiotto, Amanda
    Effinger, Meagan
    Sweetenham, John William
    BLOOD, 2009, 114 (22) : 1058 - 1059
  • [24] The impact of early stem cell transplantation on the prognosis of mantle cell lymphoma.
    Dreger, P
    Martin, S
    Kröger, N
    Kuse, R
    Sonnen, R
    Glass, B
    Parwaresch, R
    Kneba, M
    Schmitz, N
    Haas, R
    BLOOD, 1999, 94 (10) : 172A - 172A
  • [25] Dendritic cell-based therapy for the treatment of mantle cell lymphoma.
    Munger, CM
    Hentzen, A
    Vose, JM
    Bociek, RG
    Joshi, SS
    BLOOD, 2003, 102 (11) : 106A - 106A
  • [26] Dose dense, high intensity therapy for mantle cell lymphoma.
    Rizzieri, DA
    Gockerman, JP
    Moore, JO
    DeCastro, C
    Long, GD
    Vredenburgh, JJ
    Niedzwiecki, D
    Edwards, J
    Prosnitz, L
    Gasparetto, C
    Morris, A
    Lassiter, M
    Davis, P
    Chao, NJ
    BLOOD, 2001, 98 (11) : 681A - 682A
  • [27] Correlation of cytogenetic abnormalities with clinical presentation in mantle cell lymphoma.
    Onciu, M
    Schlette, E
    Abruzzo, LV
    Medeiros, LJ
    Lai, R
    MODERN PATHOLOGY, 2001, 14 (01) : 174A - 174A
  • [28] TREATMENT OF RELAPSING OR REFRACTORY MANTLE CELL LYMPHOMA. UNICENTRIC STUDY
    Marc, Sorigue
    Juan-Manuel, Sancho
    Lluis, Virgili
    Miriam, Moreno
    Cristina, Motllo
    Gustavo, Tapia
    Susanna, Gassiot
    Alberto, Pineda
    Jose-Luis, Mate
    Laura, Abril
    Monica, Linares
    Clara, Maluquer
    Edurne, Sarrate
    Ana, Triguero
    Neus, Ruiz-Xiville
    Anna, Torrent
    Susana, Vives
    Christelle, Ferra
    Blanca, Xicoy
    Montserrat, Batlle
    Gladys, Ibarra
    Immaculada, Portal
    Jose-Tomas, Navarro
    Evarist, Feliu
    Josep-Maria, Ribera
    HAEMATOLOGICA, 2016, 101 : 207 - 208
  • [29] Natural history and clinical prognosis of in situ mantle cell lymphoma.
    Kubal, Timothy Edward
    Peker, Deniz
    Sagatys, Elizabeth
    Zhang, Ling
    Naghashpour, Mojdeh
    Moscinski, Lynn
    Sotomayor, Eduardo M.
    Sokol, Lubomir
    Bello, Celeste M.
    Cultrera, Jennifer L.
    Chervenick, Paul A.
    Shah, Bijal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.
    Pindyck, T.
    Spurgeon, S. E.
    Okada, C. Y.
    Epner, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345